Although cancer genomes are replete with noncoding mutations, the effects of these mutations remain poorly characterized. Here we perform an integrative analysis of 930 tumor whole genomes and matched transcriptomes, identifying a network of 193 noncoding loci in which mutations disrupt target gene expression. These 'somatic eQTLs' (expression quantitative trait loci) are frequently mutated in specific cancer tissues, and the majority can be validated in an independent cohort of 3,382 tumors. Among these, we find that the effects of noncoding mutations on DAAM1, MTG2 and HYI transcription are recapitulated in multiple cancer cell lines and that increasing DAAM1 expression leads to invasive cell migration. Collectively, the noncoding loci converge on a set of core pathways, permitting a classification of tumors into pathway-based subtypes. The somatic eQTL network is disrupted in 88% of tumors, suggesting widespread impact of noncoding mutations in cancer.
H uman cancers are fundamentally heterogeneous, with many distinct subtypes associated with differences in molecular, cellular and clinical characteristics. To gain insight into this complexity, projects such as The Cancer Genome Atlas (TCGA) and International Cancer Genome Consortium (ICGC) have used massively parallel DNA sequencing to construct large catalogs of somatic mutations in many types of tumors [1] [2] [3] . Focusing initially on protein-coding regions, several hundred genes were found to be recurrently mutated in cancer, a few of which are targetable therapeutically 4 . As coding regions account for less than 2% of the human genome, attention is now shifting to the greater number of somatic mutations in noncoding regions 5 . Thus far, the clearest role for noncoding mutations in cancer has been in the promoter of the telomerase reverse transcriptase gene (TERT) [6] [7] [8] , with such mutations leading to increases in TERT expression levels in many types of tumors 8, 9 . Although whole-genome sequencing (WGS) of tumornormal pairs has found recurrent somatic mutations at several other noncoding loci, assessing the function of these mutations, if any, has been challenging [6] [7] [8] . In this respect, the task of functional interpretation is greatly aided by recent efforts of consortia such as ENCODE 10, 11 and Roadmap 12, 13 , which have published extensive reference maps of noncoding regions and their likely transcriptional regulatory connections to genes. Here we show that such networks provide critical information for identifying noncoding mutations with functional impacts among the many others that may be spurious 6 .
Results

Genome-wide identification of somatic eQTLs in cancer.
To identify noncoding mutations associated with functional effects, we performed a systematic analysis of 930 tumors integrating wholegenome sequences, matched mRNA expression profiles and reference transcriptional interaction maps. Using WGS of paired normal and tumor tissues in 930 patients across 22 types of cancer from TCGA 1 (Fig. 1a) , we identified 3.5 × 10 7 sites with somatic singlenucleotide variations (SNVs). We called these SNVs uniformly across all genomes using the MuTect suite 14 according to GATK best-practice recommendations 15, 16 and those of Melton et al. 6 ( Fig. 1b) . Clusters of noncoding SNVs located within 50 bp of one another were grouped, defining recurrently mutated loci (Fig. 1c , Methods and Supplementary Fig. 1 ). We then tested each locus for its association with changes in mRNA expression of target genes (Fig. 1d ). This task made use of two additional datasets. First, enhancer-gene mappings in GeneHancer 17 were used along with promoter-proximal regions, defined as sequences within 1 kb of each transcription start site (TSS), to link recurrently mutated loci to putative target genes considered to be under direct transcriptional control (Methods). Second, for the vast majority of patients with tumor genome sequences, tumor mRNA expression profiles were also available (Fig. 1a) . From these data, we developed a multivariate linear regression model of the expression change of each target gene, as a function of the mutation status of its linked loci and covariates, including the presence of copy number alterations (CNAs), DNA methylation status, tissue, ancestry and sex ( Fig. 1d and Methods). Conceptually, this procedure is similar to identifying eQTLs, in which inherited nucleotide variants are mapped to downstream functional changes 18, 19 . Here, however, the variants are somatically acquired rather than inherited. Such 'somatic eQTL analysis' simplifies the complexity and scope of eQTL mapping to a relatively small number of unlinked genetic variants: on average, 2.6 loci were tested per gene, with an s.d. of 3.1 and a maximum number of 53 ( Supplementary Fig. 1e ).
Altogether, this approach identified a cancer transcriptional network of 206 regulatory interactions between 193 somatic eQTLs and 196 gene-expression-level changes, at a false discovery rate (FDR) of 20% (Fig. 2a,b and Supplementary Fig. 2 ; somatic eQTLs at different FDR thresholds are provided in Supplementary Table 1 and the Supplementary Note). At least one locus in this network was somatically mutated in 88% of cases studied (820 of 930), suggesting that transcriptional dysregulation through noncoding mutations is a general property of most tumors. Somatic eQTLs linked noncoding mutations to the expression levels of 13 known tumor-suppressor genes or oncogenes 4, 20, 21 (Supplementary  Table 1) , although, interestingly, known cancer-associated genes were not significantly enriched overall (Fisher's exact test P = 0.3). We also found that 43% of somatic eQTLs disrupted or created a transcription factor binding motif (83 of 193; Supplementary Fig. 3 and Supplementary Table 2), although this percentage was very similar for recurrently mutated loci not detected as somatic eQTLs (40%; 2409 of 8607).
Many of the identified somatic eQTLs were frequently mutated in specific cancer tissues (Fig. 2c and Supplementary Table 3 ). Beyond the promoter of TERT, which is highly mutated in several tissues as previously noted [6] [7] [8] ( Supplementary Fig. 3a ,b), we found recurrently mutated loci associated with expression of DHX34 (mutated in 43% of diffuse large B cell lymphoma), TUBBP5 (29% of lymphomas and 17% of liver cancers), HYI (21% of melanoma), and PCDH1 (19% of acute myeloid leukemia), among others. While most of the somatic eQTLs were mutated in multiple tissues, 12 of the somatic eQTLs were mutated almost exclusively in melanoma (80% or more of the mutations occurred in melanoma). Such enrichment for a single tissue was not seen for any other tissue type.
Somatic eQTLs are recurrently mutated in a second cohort. To systematically validate this network, we examined an independent pan-cancer cohort from ICGC consisting of genome-wide somatic mutation calls for 3,382 patients 2 . Notably, we found that the majority of the somatic eQTLs identified in the original TCGA discovery set were recurrently mutated in the ICGC validation cohort (107 of the 193 at FDR < 20%; Fig. 2d ). These included 10 of the 12 melanoma eQTLs, which again were frequently and almost exclusively mutated in the melanoma samples in ICGC (Fisher's exact test P = 4.1 × 10 Increasing DAAM1 expression leads to cell invasion. We next sought to examine in more detail the somatic eQTL located 191 bp upstream of DAAM1 ( Fig. 2a and Methods), which is recurrently mutated in patients with melanoma who have metastatic disease in both cohorts (Fig. 2c,d ). The DAAM1 protein forms a complex with Dishevelled and RhoA to recruit the actin cytoskeleton, which is thought to increase the motility and invasiveness of cancer cells in response to Wnt signaling [22] [23] [24] . Mutations at this somatic eQTL are associated with increased DAAM1 mRNA expression levels potentially owing to the loss of an E2F motif and the gain of an Ets motif ( Fig. 3a ; NC_000014.8:g.59655190 G > A). To confirm a causal relationship between the somatic eQTL and gene expression level changes, wild-type and mutant DAAM1 regulatory elements were inserted upstream of the GFP gene (Fig. 3b) . Analysis by flow cytometry showed that the mutated regulatory element led to a significantly higher percentage of cells expressing GFP in melanoma, sarcoma and breast cancer cell lines (Fig. 3c,d and Supplementary  Fig. 4) . Furthermore, the GFP-expressing cells had significantly higher levels of GFP expression with the mutant rather than the wild-type DAAM1 element in all four cell lines tested ( Fig. 3d and Supplementary Fig. 4c,e,g ).
We also explored the functional relationship between increased DAAM1 expression and cell motility, using an established 3D collagen hydrogel matrix model 25 . Genome-wide mRNA sequencing was performed on cells grown within low-or high-density collagen, mimicking the stiffness of normal or tumor tissues and eliciting less and more invasive phenotypes, respectively 26, 27 (Methods). In these experiments, DAAM1 was one of the most upregulated transcripts under invasive conditions 28 ( Supplementary Fig. 5 ). To test whether invasion was functionally dependent on DAAM1, we quantified cell migration behavior after DAAM1 expression was increased artificially by exogenous overexpression (Fig. 3e , Methods and Supplementary  Fig. 6e ). When cells overexpressing DAAM1 were embedded in the 3D collagen hydrogel, they migrated with significantly greater persistence than did wild-type cells (P = 0.008, two-sided Mann-Whitney U test; Supplementary Fig. 6a ). Cells overexpressing DAAM1 also invaded for longer distances than wild-type cells (P = 0.01, two-sided Mann-Whitney U test; Fig. 3f-h) , while retaining the same velocities as wild-type cells ( Supplementary Fig. 6b,c) . This invasive phenotype was observed in the absence or presence of additional Wnt5a signaling ( Supplementary Fig. 6d ). These results suggest that increased DAAM1 expression levels allow cells to more efficiently invade the local microenvironment, thereby linking this noncoding mutation to DAAM1 overexpression and cell invasion.
Noncoding mutations dysregulating MTG2 and HYI. Beyond DAAM1, we examined two additional somatic eQTLs, one in the promoter of MTG2 ( + 19 to + 33) and another in the enhancer of HYI ( + 95,097 to + 95,132) (Methods). The first eQTL was associated with decreased MTG2 mRNA expression levels, likely owing to the disruption of a HIF-1β binding motif by the G-to-A mutation 19 bp downstream of the TSS (Fig. 4a ; NC_000020.10:g.60758100 G > A). This somatic eQTL was present in several types of cancer, including lung adenocarcinoma and sarcoma. Using another GFP-based reporter assay of promoter activity, we found that this G-to-A mutation greatly decreased reporter gene expression in both A549 lung epithelial carcinoma cells and U2OS bone osteosarcoma cells (Fig. 4b) . The second eQTL was present in 21% of melanomas (Fig. 2c ) and was associated with increased HYI mRNA expression levels, likely owing to G-to-A or GG-to-AA substitutions altering an Ets family binding motif ( Fig. 4c ; NC_000001.10:g.43824528 G > A, NC_000001.10:g.43824529 G > A, or NC_000001.10:g.43824528_43824529GG > AA). As this somatic eQTL was present in an enhancer region, we used a luciferase-based reporter assay where regulatory elements were cloned upstream of a mini-promoter and luciferase. We found that two of the three HYI enhancer variants led to increased expression levels relative to the wild-type sequence in both A375 melanoma cells and MDA-MB-231 breast cancer cells (Fig. 4d) . Noncoding and coding mutations converge on pathways. Next, we investigated the relationship between the 196 genes transcriptionally regulated by somatic eQTLs and the 138 genes previously documented to have recurrent coding mutations in cancer 21 . This combined set of genes was analyzed by Network-Based Stratification (NBS) 29, 30 ( Fig. 5a ), which uses a reference molecular network to implicate network regions associated with the genetic alterations in a tumor and groups tumors into subtypes on the basis of similarity of these implicated regions. As a reference molecular network, we used ReactomeFI 31 , documenting 229,300 interactions among 12,177 human gene products pertaining to previously reported protein-protein, transcriptional and metabolic interactions.
This approach identified a collection of network regions (henceforth called 'pathways' for simplicity) that stratified tumors into a hierarchy of increasingly specific subtypes (Fig. 5b) . At a resolution of ten subtypes, each subtype was enriched in 2-5 tumor tissues and tumors of each tissue could be subdivided into 1-3 subtypes ( Supplementary Fig. 7 ). Nonetheless, these subtypes differed significantly in their implications for disease-free survival, beyond the baseline survival for each tissue (P = 3.3 × 10
, log likelihood ratio test controlling for the tissue types as covariates; Fig. 5c and Supplementary Fig. 8 ).
Subtypes aggregating noncoding and coding mutations. Among the ten subtypes, four were of particular interest as they contained a large proportion of patients with noncoding mutations (Fig. 5d) . The 'CDKN2A-EGFR-TERT subtype' (Fig. 5e ,f) was defined by disruption of the CDKN2A coding sequence, sometimes in combination with noncoding mutations to the TERT promoter, EGFR activation, or BRAF activation. CDKN2A encodes p14 ARF , which can form a complex with HIF-1α and inhibit HIF-1-mediated transcription of TERT 32, 33 . These loss-of-function mutations in CDKN2A may release a key brake on the activity of hTERT. Separately, gain-of-function mutations in EGFR may lead to increased levels of mTOR phosphorylation and activation 34 , which can upregulate telomerase activity by forming a complex with hTERT 35 . The synergy between BRAF and TERT mutations has been previously noted and attributed to modulation of TERT transcription through BRAF-RAS-ERK signaling 36 . This pathway was also linked to DAAM1 promoter mutations ( Fig. 5d ), validated previously, as DAAM1 forms a complex with Dishevelled (DVL3) 22, 23 , which indirectly regulates transcription of CDKN2A and EGFR through inhibition of Notch1 37 . This subtype was the most aggressive, with median disease-free survival time at 13 months ( Fig. 5c) .
A second subtype of interest, the 'TERT-BRAF-IDH1 subtype' (Supplementary Fig. 9 ) was characterized by tumors with TERT noncoding mutations or amplifications, combined in some patients with coding alterations to functionally related genes such as BRAF and SKP2. Beyond the synergy between BRAF and TERT mutations as described above, SKP2 is essential for ubiquitination and degradation of p27 KIP1 (encoded by CDKN1B)
38
, which inhibits the activity of hTERT 39 . Amplification of SKP2 in this pathway may thus increase the activity of hTERT.
A third subtype, 'PIK3CA-PEX26-GATA3' (Fig. 5g,h ), integrated coding alterations activating PIK3CA and inactivating GATA3 with noncoding alterations downregulating PEX26. In this pathway, members of the peroxisomal biogenesis factor family (PEX26 and PEX6) appear to indirectly interact with PIK3CA and GATA3 through the binding of SMAD family members (SMAD3 and SMAD7) 40 . Finally, the fourth subtype, 'APOBEC2-ARID1A-CTNNB1' , was characterized by the co-occurrence of noncoding mutations within an enhancer of APOBEC2 and coding alterations in ARID1A and CTNNB1. APOBEC2 encodes a nucleic-acid-editing enzyme with well-known mutagenic effects in cancer 41 . Although ARID1A and CTNNB1 are also known cancer drivers, the connections to APOBEC are unanticipated and create a compelling opportunity for further study. 
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Gain of function Coding mutation Noncoding mutation Both key structural and functional data on transcriptional networks. Structurally, maps of enhancer-and promoter-gene interactions amplify signal by selecting noncoding mutations within defined regulatory regions of specific target genes. These mutations are then characterized functionally as somatic eQTLs by requiring their presence to be significantly associated with expression changes in tumors. The result is a global network of transcriptional regulatory interactions in cancer supported by multiple lines of evidence.
Given that most tumors we analyzed had noncoding mutations affecting some part of this network, such mutations appear to represent a widespread feature of cancer biology.
Of the approximately 200 noncoding mutations that have previously been identified as recurrent in cancer [6] [7] [8] , one-third were also identified here as recurrently mutated loci (Fig. 1c) , including wellknown mutations in the promoters of PLEKHS1 and DPH3. Notably, though, with the exception of TERT, these mutations did not associate significantly with mRNA expression level changes. This suggests that the effects of these mutations are through mechanisms outside of transcriptional regulation or that the effects on mRNA expression are weaker than could be detected given our statistical power ( Supplementary Fig. 2c ). On the other hand, hundreds of somatic eQTLs were identified, all of which were unanticipated other than those in the promoter of TERT. Many of the affected genes are not yet widely appreciated as cancer drivers, motivating further studies on the mechanistic basis of noncoding mutations in cancer.
Given an association between gene expression changes and a somatic mutation, it is important to consider whether this association reflects a causal relationship. Although it is tempting to assume that the occurrence of a mutation drives gene expression changes, the opposite could be true, where the change in gene expression levels drives the appearance of the mutation (for example, by increased opening and exposure of chromatin). It is also possible that both effects could be due to a third causal factor. However, the three examples we tested experimentally do support a causal link from mutation to expression changes. These results include transcriptional alterations of DAAM1, impacting cell migration ( Fig. 3 and Supplementary Fig. 4) ; MTG2, which encodes a GTPase that regulates mitochondrial ribosomes 42 (Fig. 4a,b) ; and HYI, which encodes a putative hydroxypyruvate isomerase and may be involved in carbohydrate transport and metabolism 43 (Fig. 4c,d ). Finally, the somatic eQTL analysis introduced here contrasts with germline eQTL studies in several key aspects. First, in GWAS and germline eQTL studies, testing of multiple SNPs is complicated by the strong codependencies among neighboring SNPs at a genomic locus-so-called linkage disequilibrium 44, 45 . In contrast, somatic mutations near to one another in the genome are not in linkage disequilibrium as these alterations, by definition, arise independently in each tumor. Second, population stratification caused by ancestry diversity has been a major confounder in the analysis of germline variants 44, 45 . It is less of a concern for somatic variants, as these are derived from comparisons between tumor and normal genomes from the same individual, eliminating many, if not all, effects due to ancestry. Nonetheless, we controlled for ancestry diversity and found that the impact on somatic eQTL discovery was minimal. Given these aspects, somatic eQTL analysis may have future interest alongside classical eQTLs as a general mode of mapping transcriptional regulatory architecture.
URLs. TCGA Research Network, http://cancergenome.nih.gov/; Firehose, https://confluence.broadinstitute.org/display/GDAC/ Home; TCGA RNA-seq data description, https://wiki.nci.nih.gov/ display/TCGA/RNASeq + Version + 2; poibin Python package, https://github.com/tsakim/poibin; HOMER, http://homer.ucsd.edu/ homer/index.html; somatic mutations of the 930 tumors, http:// ideker.ucsd.edu/papers/wzhang2017/; GitHub site for custom code, https://github.com/wzhang1984/Noncoding-tumor-mutation-paper.
Methods
Methods, including statements of data availability and any associated accession codes and references, are available at https://doi. org/10.1038/s41588-018-0091-2. (Fig. 1a) , this set was again filtered to remove those altered in fewer than k tumors within the subset. We also calculated a 'concentration score' to penalize loci where mutations were spread over a large region rather than concentrated at a single base pair, as might be expected for sites affecting gene transcription. Within each locus, we selected the mutated position present in the largest number of patients. The proportion of patients affected at that position (out of all patients affected by mutations at that locus) was defined as the concentration score. Loci scoring < 35% were removed from further study. It is worth noting that the threshold for the concentration score is somewhat arbitrary and could lead to certain loci with multiple closely located somatic mutations being missed. It should also be noted that, by clustering noncoding mutations into loci, we assume that all SNVs in a locus act in a similar way. This assumption is consistent with the previously identified SNVs in the TERT promoter. Our analysis does not attempt to detect loci in which different SNVs alter gene expression in opposite directions.
RNA-seq, CNA and DNA methylation data processing. RNA-seq, CNA (SNP 6.0) and DNA methylation (Illumina HM450) data for TCGA tumors were downloaded from Firehose (see URLs). The data were processed as follows. First, for RNA-seq, the RSEM count for a gene (RNA-seq by expectation maximization) 47 was normalized by dividing by the 75th percentile of RSEM values within the tumor sample and multiplying by 1000, according to TCGA practice (see URLs). Genes were retained if the normalized RSEM was > 1 in > 50% of tumors, resulting in 16,413 expressed genes. Normalized RSEM values were log 2 transformed and z score standardized for subsequent analyses. Second, for CNAs, we used the output of GISTIC2, which indicates gene-level CNAs for all samples. The CNAs are in units of (copy number -2), so that normal copy number (no amplification or deletion) has a value of 0, whereas genes with amplifications have positive values and genes with deletions have negative values. A gene is assigned the highest amplification or the lowest deletion value among the markers it covers. Among the 783 patients with both mRNA expression and genome sequence data, 761 also had copy number data available. The remaining patients were assigned 0 for all CNAs. Third, methylation probes were mapped to the promoter regions of genes ( ± 1 kb from the TSS), and each gene was assigned the mean methylation (beta) values of these probes. Among the 783 TCGA patients with both mRNA expression and genome sequences data, 605 had methylation data available. Methylation data for the remaining patients were imputed using mean values for the DNA methylation of each gene.
Linking recurrently mutated loci to transcriptional target genes. Our recurrently mutated loci were extended by 100 bp on each side when mapping to promoters or enhancers. Transcriptional regulatory interactions from recurrently mutated loci to target genes were defined whenever a locus had 50% of its sequence overlap with either the promoter region of a gene ( ± 1 kb from its TSS) or a gene enhancer region defined by GeneHancer 17 . In the case where an enhancer was shorter than a locus, the mapping was performed when 50% of the enhancer sequence overlapped with the locus. The hidden factors h were identified using probabilistic estimation of expression residuals (PEER) 48, 49 , while accounting for the effect of known covariates t, r and g. The number of hidden factors was determined by the posterior variance of the factor weights, as previously recommended 49 . The parameters β were estimated from data from 783 tumors with matched RNA-seq and WGS data. Somatic eQTLs were identified as follows. First, for each gene, we selected features by adding an L1-norm to the objective function based on the least-squared error between the true and predicted gene expression levels.
The sparsity parameter λ was optimized by cross-validation. For genes in which the L1-norm resulted in β 1 = 0 for all loci, we decreased λ to include at least one locus. Second, to assess whether the mutation status of any locus contributed significantly to gene expression, the accuracy of the complete model was compared to that of a simple model under the null hypothesis of no genetic associations (i.e., β 1 = 0 for all loci). The F-test P value between the two nested models was used as the test statistic. Third, having derived an F-test P value for each gene, q values were calculated using the Storey approach 50 with a threshold of FDR ≤ 20%. And finally, for each gene that passed the selection, this threshold was mapped back to the equivalent F-test P value of each locus. Loci with F-test P values below or equal to this threshold were included in the final list and defined as somatic eQTLs.
We elected to perform one test per gene for three reasons. First, in GWAS and typical (germline) eQTL studies, linkage disequilibrium complicates the simultaneous testing of multiple SNPs in a single model because these SNPs are usually codependent. Unlike inherited SNPs, somatic mutations observed in a tumor population are not in linkage disequilibrium no matter how closely they are located. Therefore, a simple F test, which assumes independent influences of multiple factors, is sufficient to simultaneously test whether any loci are associated with gene expression. Second, for each gene, all eQTLs share the same set of covariates along with the associated phenotype of mRNA expression level. If multiple eQTLs are associated with gene expression levels, they can be covariates of one another. It is then convenient to fit them all in a single model and enjoy the benefit of gene-based approaches such as feature selection by L1 regularization. Third, there is precedent in the literature to fit gene-level models in eQTL studies 51, 52 .
Power analysis. Statistical power depends on various parameters, including the number of samples, the eQTL effect size, the noise, and the significance threshold. Instead of a simulation based on a model of noise, we evaluated statistical power using the actual data. All locus-gene pairs were plotted in Supplementary Fig. 2c , evaluated by the number of patients with mutations (x axis) versus the change in gene expression given the mutation (y axis; defined by = .
. For each eQTL, the number of mutated patients k was used as the test statistic. To determine whether k was greater than expected owing to the background mutation rate (BMR), we developed an approach for estimating BMR that was conceptually similar to MutSigCV 53 . First, a large pool of 20,000 candidate background sequences was created by randomly reassigning (without replacement) the location of the eQTL to the same type of noncoding genomic regions (promoters or putative enhancers 17 ) while retaining the eQTL's length. Each of these 20,000 sequences was placed in a 3D feature space taking into account nucleotide content, DNA replication timing and gene expression. Nucleotide content was represented as the percentages of all possible mononucleotides (A/T versus C/G), dinucleotides (e.g., AA, AC and AG) and trinucleotides (for example, AAA, AAC and AAG), encoded as a 44-dimensional vector. This information was then compressed into a single feature representing nucleotide content, using the Pearson's correlation between the vector of the candidate sequence and the vector of the original eQTL. DNA replication timing was obtained from ENCODE via the UCSC Genome Browser 54 . To create a single replication timing feature, we used the average wavelet-smoothed signal from the following 14 cell lines: BJ, GM06990, GM12801, GM12812, GM12813, GM12878, HeLa-S3, HepG2, HUVEC, IMR-90, K562, MCF-7, NHEK and SK-N-SH, according to the method of Melton and colleagues 6 . For gene expression, the median expression value of the nearest gene (log 2 -transformed RNA-seq data, 783 TCGA patients) was used as a feature. The above three features were z score standardized. Within this feature space, the top 5% (1,000 of 20,000) background sequences with the smallest Euclidean distance to the eQTL of interest were selected. For each patient, a patient-specific BMR was estimated as the number of sequences with at least one mutation in that patient out of the 1,000 selected sequences. Finally, we estimated the probability of having observed k or more mutations in n patients in the eQTL of interest using a Poisson binomial model
where F l is the set of all subsets of k integers that can be selected from {1, 2, … , n}, p i or p j is the probability that patient i or patient j is mutated, A is a set of k integers that can be selected from {1, 2,… , n} and A c is the complement of A. In practice, we used an approximation for the Poisson binomial in the poibin Python package (see URLs).
Transcription factor binding motif analysis. Each reference and somatically altered nucleotide site, along with ± 7 bp of flanking sequence, was analyzed using HOMER 55 (see URLs). HOMER searches for matches within a library of 319 vertebrate motifs (position weight matrices). Specifically, we ran the findMotifs.pl program with default parameters to find motifs from FASTA files. The reference and altered sequences were used as the background for each other to control the nucleotide context. The command line is findMotifs.pl seqList_mappable_alt.fa fasta log/ -fastaBg seqList_mappable_ref. fa -p 16 -find ~/soft/homer/data/knownTFs/vertebrates/known.motifs
The list of somatic eQTLs that disrupt or create transcription factor binding motifs in four or more patients is reported in Supplementary Table 2.
Prioritizing somatic eQTLs for subsequent functional validation. The three somatic eQTLs selected for functional studies (DAAM1, HYI1 and MTG2) were chosen based on the specific biological interest of the authors and several rules of thumb:
1. The somatic eQTL alters a known transcription factor binding motif in many patients; 2. The somatic eQTL falls in open chromatin in previously mapped cell lines and conditions (for example, in regions with markers such as H3K27ac and H3K4me1) 11 ; 3. The affected target gene has high endogenous mRNA expression levels in cell lines 56 that match where the somatic eQTL was detected; 4. The somatic eQTL is not present in a region with repetitive DNA.
Note that none of this information was used to filter loci before somatic eQTL analysis, as it is not complete, conclusive or cancer specific.
Generation of reporter plasmids.
To examine the effect of the DAAM1 somatic eQTL on gene expression levels, the wild-type and mutant regulatory regions, from − 233 bp to + 148 bp relative to the TSS, including the somatic eQTL at − 202 to − 191 bp, were synthesized and cloned upstream of GFP (Fig. 3b) . For MTG2, the cloned region spanned − 200 bp to + 200 bp relative to the TSS, including the somatic eQTL at + 19 to + 33 bp.
For the somatic eQTL located in the HYI enhancer, the region corresponding to + 94,931 to + 95,332 bp relative to the TSS, including the somatic eQTL at + 95,097 to + 95,132 bp, was cloned into the firefly luciferase reporter plasmid pGL4.23 (Promega). Mutations were generated using the Q5 Site-Directed Mutagenesis kit (New England BioLabs). All inserts for the GFP and luciferase reporter plasmids were confirmed to match the human reference genome hg19 by Sanger sequencing.
Promoter and enhancer activity assays. Cell lines used to evaluate promoter activity were plated in six-well dishes at 300,000 cells per well, with three replicates per group. The next day, plasmid DNA (1 μ g) was transfected using Lipofectamine 3000 (Thermo Fisher). Forty-eight hours after transfection, cells were harvested and suspended in ice-cold PBS with 1% FBS. GFP expression was measured by flow cytometry on a FACSCalibur or FACSCanto (BD Biosciences). Flow cytometry data were analyzed with FlowJo v10 (BD Biosciences). Cells with typical forward (size) and side (granularity) scatter properties were further analyzed for GFP expression. As a negative control, cells were transfected with an empty lentiGuide-Puro plasmid (Addgene) for the DAAM1 experiments (Fig. 3c,d and Supplementary Fig. 4 ) or a promoterless GFP plasmid (pRMT-tGFP, Origene) for the MTG2 experiments (Fig. 4b) . As a positive control for all GFP experiments, we used a plasmid with the cytomegalovirus promoter upstream of GFP. All flow cytometry experiments were performed at least three times. Early pilot experiments were often performed on single or duplicate samples with the final triplicate version often performed at least twice.
To evaluate the activity of the enhancer region of HYI, A375 and MDA-MB-231 cells were plated in white, opaque, 96-well plates at 10,000 cells per well, with four replicates per group. Cells were transfected 24 h later using Lipofectamine 3000 with 33 ng of total DNA: 27.5 ng of the firefly pGL4.23 constructs and 5.5 ng of control Renilla pGL4.75 (Promega) plasmid. Firefly and Renilla luciferase activities were measured 48 h after transfection using the Dual-Glo Luciferase Assay System (Promega) according to the manufacturer's instructions. Luciferase values were collected on a BioTek Synergy HT, and data were collected via Gen5 2.01.14 software. To calculate relative luciferase values, background signal was first subtracted from each channel. Then, firefly luminescence was divided by Renilla luminescence. The average value for the wild-type enhancer was set to 1, and the mutated samples were evaluated in comparison to this control. Experiments in both cell lines were performed three times, with each experiment consisting of samples in quadruplicate.
DAAM1 overexpression. Wild-type MDA-MB-231 breast cancer cells were transfected with a plasmid encoding the full DAAM1 cDNA (Origene, RC217675). Cells were then selected using G418 (500 μ g/ml) for 7 d to ensure stable expression of the DAAM1 construct. DAAM1 overexpression was verified by extracting total protein and quantifying using the Wes electropherogram (Proteinsimple) with anti-DAAM1 antibody (clone WW-3, sc-100942, lot B1815, Santa Cruz, 1:250 dilution) and anti-tubulin antibody (clone YL1/2, MAB1864, lot 2886723, Millipore, 1:250 dilution). DAAM1 expression was 5.5-fold greater in cells with the DAAM1 overexpression construct relative to wild-type cells (Supplementary Fig. 6e ).
3D collagen cell migration assays. Collagen matrices were prepared by mixing cells suspended in culture medium and 10 × reconstitution buffer, one-to-one with soluble rat tail type I collagen in acetic acid (Corning) 25 . Sodium hydroxide was used to normalize pH (pH 7.0, 10-20 μ l 1 M NaOH), and the mixture was placed in 48-well culture plates for polymerization at 37 °C. Final gel volumes were approximately 200 μ l with the final collagen concentration set to 2.5 mg/ml. The polymerized cell-laden hydrogels were incubated for 24 h under a standard cell culture environment before imaging. Gels were then transferred to a microscope stage-top incubator, and cells were imaged at low magnification (10 × ) every 2 min for 48 h. The coordinates of cell location in each time frame were determined using image recognition software (Metamorph/Metavue, Molecular Devices). Tracking data were processed to calculate cell speed using an extension of previously published scripts 57 . Cell migration assays (Fig. 3f-h) were performed two times, and both attempts showed the same trend.
RNA sequencing from cells in 3D culture. In Supplementary Fig. 5 , cell migration assays were performed using wild-type MDA-MB-231 breast cancer cells and HT-1080 fibrosarcoma cells. 3D collagen I gels were seeded in three independent experiments and harvested after 24 h of culture for RNA extraction and directly homogenized in TRIzol reagent (Thermo Fisher). Total RNA was purified using the High Pure RNA Isolation kit (Roche), and the integrity of the sample was verified using RNA Analysis ScreenTape (Agilent Technologies). Total RNA samples were sequenced using the TruSeq Stranded mRNA Sample Prep kit (Illumina) and the Illumina MiSeq platform at a depth of > 25 million reads per sample. Paired-end reads were aligned to the hg19 UCSC human genome reference using Bowtie2 58 and streamed to eXpress 59 for transcript abundance quantification.
Tumor genetic profiles integrating noncoding and coding alterations. Integrated genetic alteration profiles were constructed for the 810 tumors with WGS, WES and CNA data (Fig. 1a) as follows. Known oncogenes or tumor suppressors 21 were combined with the set of target genes of eQTLs identified by the somatic eQTL analysis (see above); each of these genes was then classified as wild type (0) or altered (1) in each tumor, constituting its tumor genetic profile. In this profile, an alteration was defined as follows. Most oncogenes (for example, EGFR) were considered altered (activated) if impacted by a missense mutation, in-frame indel or copy number amplification. For oncogenes typically altered only by amplification 21 (CCND1, MDM2, MDM4, MYC, MYCL, MYCN, NCOA3 and SKP2), only copy number amplifications were considered as alterations and not SNVs or indels. Tumor suppressors (for example, CDKN2A) were considered altered (inactivated) if there was any type of non-silent mutation or a copy number deletion. For each target gene, we defined a dominant direction of regulation d ∊ { + 1, − 1} as the sign of the coefficient (β 1 in equation (1)) of its most significantly associated eQTL. Noncoding mutations in eQTLs that led to a transcriptional change in the dominant direction were considered alterations of such genes. For TERT, copy number amplifications in the coding region were also considered as alterations, as both promoter mutations and gene amplifications have been associated with growth advantage of tumor cells and poor prognosis of patients 60, 61 .
Network-based stratification to identify tumor subtypes. Network propagation 29 was used to compute the pairwise similarities among tumor genetic alteration profiles (see above) within the Reactome functional interaction network (ReactomeFI) 31 . Each tumor genetic profile was propagated across this network on the basis of a random walk model (equivalent to heat diffusion) with a restart probability of 0.5. After convergence, the score of each gene (temperature) represents its network proximity to genetic alterations. The top 70 principal components of these scores, representing the tumor's network-transformed profile (Fig. 5a) , were analyzed using the sklearn.cluster.SpectralClustering package 62 (affinity = k-Nearest-Neighbors, assign-labels = discretize, n_clusters = [2… 10]). This method first constructs a similarity graph on all pairs of tumors, where each tumor is connected to the k others with the shortest Euclidean distance. We chose k = 170, which ensures that the similarity graph is connected, as previously recommended 62 . Next, this graph is analyzed to partition tumors into subtypes at different resolutions (number of subtypes n = [2… 10]). Following spectral clustering, each set of n (parent) subtypes was compared to the n + 1 (child) subtypes to track the similarity of tumor assignments (Fig. 5b ). An arrow was drawn from a parent to child subtype if they shared ≥ 18 tumors.
Characterizing tumor subtypes with signature genes and subnetworks. For each subtype, we defined a set of 'signature genes' as those that had higher networktransformed scores in that subtype than others (t test, Benjamini-Hochberg FDR < 0.1) and, among these, were more frequently altered in that subtype (Fisher exact test, FDR < 0.05; Fig. 5b-e) . To identify subnetworks, this set was expanded to include 'intermediate genes' with relatively high network-transformed scores (t test, FDR < 0.05) that lay on the shortest paths between each pair of signature genes. The union of the signature and intermediate genes was used to induce a subnetwork within ReactomeFI 31 , referenced in the main text as the corresponding 'pathway' impacted in that subtype (Fig. 5d ). An additional filter was applied in Fig. 5e and Supplementary Fig. 9a , where we only visualized the signature genes with ten or more mutations and the shortest paths among them with at most one intermediate gene. All networks were visualized in Cytoscape 63 .
Survival analysis. We used the coxph package in R statistical software to fit Cox proportional-hazard models 64 . P values were calculated by log likelihood ratio test. To evaluate whether the subtype classifications provided additional prognostic power beyond the baseline survival expectancy due to cancer tissue, we compared the likelihood for the complete model, including NBS-derived molecular subtypes s and cancer tissues c as covariates, against that of a null model that included cancer tissues c only (Fig 3, Fig 4, Sup Fig 4) were performed in three independent cell culture replicates (Sup Table 5 ). Each triplicate consists of 50,000 events counted through the flow counter. Although the sample size was not pre-determined, it proved sufficient to observe a very significant difference in % GFP+ and GFP intensity (two-tailed t-test p = 5.63E-07 to 5.74E-04). Experiments with this sample size are in accordance to conventions in this field.
For the luciferase assays (Fig 4d) , each experiment was performed in four independent cell culture replicates (Sup Table 6 ). Although the sample size was not pre-determined, it proved sufficient to observe a very significant difference in % GFP+ and GFP intensity (two-tailed t-test p = 4.60E-08 to 6.21E-03). Experiments with this sample size are in accordance to conventions in this field.
In the cell migration assay, 74 and 83 cells were imaged in the two groups in Fig. 4h and Sup Figs 6a-c, and 63 and 15 cells were images in Fig 6d. The sample size is sufficient to observe a significant difference in invasion distance, persistence, and invasion distance with additional Wnt5a signaling (two-tailed Mann-Whitney U test p = 0.01, 0.008, and 0.0002, respectively).
In somatic eQTL analysis (Fig 2a) , all 783 TCGA tumors with both genome sequence and mRNA expression data were used for the study. The sample size is sufficient to identify 193 somatic eQTLs at a FDR of 20% (F-test).
In the validation of somatic eQTL recurrence (Fig 2d) , all 3,382 publicly available non-US ICGC tumors with whole genome sequence data were used for the study. The sample size is sufficient to validate that the majority of the somatic eQTLs identified in the original TCGA discovery set were recurrently mutated in the ICGC validation cohort (107 of the 193 at an empirical FDR of 20%).
In the RNA-seq analysis ( Sup Fig 5b) , each experiment was performed in three independent cell cultures. Although the sample size was not pre-determined, it proved sufficient to observe a significant difference in DAAM1 expression (twotailed t-test p = 0.056 and 0.016). Experiments with this sample size are in accordance to conventions in this field.
Data exclusions
Describe any data exclusions. No data were excluded from the analysis.
Note that in our analysis, although loci were selected in a series of consecutive steps (Figs 1c, d ), each locus was tested in the full set of tumors (n = 783) for which whole genome sequence and mRNA expression are both available.
Replication
Describe whether the experimental findings were reliably reproduced.
All flow cytometry experiments were performed at least three times. Early pilot experiments were often performed on single or duplicate samples with then the final triplicate version often also performed at least twice. The figure presented always represented the majority of experimental findings.
All luciferase assays experiments were performed three times, with each experiment consisting of samples in quadruplicate. The figure presented always represented the majority of experimental findings.
Cell migration assays (Fig. 4f-h ) were performed two times and both attempts showed the same trend.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
No method of randomization was used.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
The investigators were not blinded to group allocation during data collection and/ or analysis.
Note: all studies involving animals and/or human research participants must disclose whether blinding and randomization were used.
Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section) For manuscripts utilizing custom algorithms or software that are central to the paper but not yet described in the published literature, software must be made available to editors and reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). Nature Methods guidance for providing algorithms and software for publication provides further information on this topic.
